Friday, October 28, 2016

Vicnite




Vicnite may be available in the countries listed below.


Ingredient matches for Vicnite



Diphenhydramine

Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Vicnite in the following countries:


  • Mexico

International Drug Name Search


Doxinvarise




Doxinvarise may be available in the countries listed below.


Ingredient matches for Doxinvarise



Calcium Dobesilate

Calcium Dobesilate is reported as an ingredient of Doxinvarise in the following countries:


  • Peru

International Drug Name Search


Vaira




Vaira may be available in the countries listed below.


Ingredient matches for Vaira



Olanzapine

Olanzapine is reported as an ingredient of Vaira in the following countries:


  • Croatia (Hrvatska)

International Drug Name Search


Thursday, October 27, 2016

Hidroxiurea Dosa




Hidroxiurea Dosa may be available in the countries listed below.


Ingredient matches for Hidroxiurea Dosa



Hydroxycarbamide

Hydroxycarbamide is reported as an ingredient of Hidroxiurea Dosa in the following countries:


  • Argentina

International Drug Name Search


Dimetilsolfossido




Dimetilsolfossido may be available in the countries listed below.


Ingredient matches for Dimetilsolfossido



Dimethyl Sulfoxide

Dimetilsolfossido (DCIT) is known as Dimethyl Sulfoxide in the US.

International Drug Name Search

Glossary

DCITDenominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Docetaxel Servycal




Docetaxel Servycal may be available in the countries listed below.


Ingredient matches for Docetaxel Servycal



Docetaxel

Docetaxel is reported as an ingredient of Docetaxel Servycal in the following countries:


  • Argentina

International Drug Name Search


Nausea




Nausea may be available in the countries listed below.


Ingredient matches for Nausea



Domperidone

Domperidone is reported as an ingredient of Nausea in the following countries:


  • Japan

International Drug Name Search


Dirithromycine




Dirithromycine may be available in the countries listed below.


Ingredient matches for Dirithromycine



Dirithromycin

Dirithromycine (DCF) is known as Dirithromycin in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Zolazepam Hydrochloride




Zolazepam Hydrochloride may be available in the countries listed below.


Ingredient matches for Zolazepam Hydrochloride



Zolazepam

Zolazepam Hydrochloride (BAN, USAN) is also known as Zolazepam (Rec.INN)

International Drug Name Search

Glossary

BANBritish Approved Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Dequalinium DHA




Dequalinium DHA may be available in the countries listed below.


Ingredient matches for Dequalinium DHA



Dequalinium Chloride

Dequalinium Chloride is reported as an ingredient of Dequalinium DHA in the following countries:


  • Hong Kong

International Drug Name Search


Venlaxor




Venlaxor may be available in the countries listed below.


Ingredient matches for Venlaxor



Venlafaxine

Venlafaxine is reported as an ingredient of Venlaxor in the following countries:


  • Georgia

  • Latvia

International Drug Name Search


Supresol




Supresol may be available in the countries listed below.


Ingredient matches for Supresol



Methylprednisolone

Methylprednisolone 21-(sodium succinate) (a derivative of Methylprednisolone) is reported as an ingredient of Supresol in the following countries:


  • Italy

International Drug Name Search


Cough and Nasal Congestion Medications


Drugs associated with Cough and Nasal Congestion

The following drugs and medications are in some way related to, or used in the treatment of Cough and Nasal Congestion. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Cough and Nasal Congestion





Drug List:


Midamor


Midamor is a brand name of amiloride, approved by the FDA in the following formulation(s):


MIDAMOR (amiloride hydrochloride - tablet; oral)



  • Manufacturer: PADDOCK LLC

    Approved Prior to Jan 1, 1982

    Strength(s): 5MG [AB]

Has a generic version of Midamor been approved?


Yes. The following products are equivalent to Midamor:


amiloride hydrochloride tablet; oral



  • Manufacturer: SIGMAPHARM LABS LLC

    Approval date: January 30, 2009

    Strength(s): 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Midamor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Midamor.

See also...

  • Midamor Consumer Information (Wolters Kluwer)
  • Midamor Consumer Information (Cerner Multum)
  • Midamor Advanced Consumer Information (Micromedex)
  • Midamor AHFS DI Monographs (ASHP)
  • Amiloride Consumer Information (Wolters Kluwer)
  • Amiloride Consumer Information (Cerner Multum)
  • Amiloride Advanced Consumer Information (Micromedex)
  • Amiloride Hydrochloride AHFS DI Monographs (ASHP)

Wednesday, October 26, 2016

Sasulen Topico




Sasulen Topico may be available in the countries listed below.


Ingredient matches for Sasulen Topico



Piroxicam

Piroxicam is reported as an ingredient of Sasulen Topico in the following countries:


  • Spain

International Drug Name Search


Sorini




Sorini may be available in the countries listed below.


Ingredient matches for Sorini



Nimesulide

Nimesulide is reported as an ingredient of Sorini in the following countries:


  • Philippines

International Drug Name Search


Miscellaneous genitourinary tract agents


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Genitourinary tract agents are medicines, which are used to treat conditions of the reproductive organs and excretory system or urinary tract. They include medicines used for bladder spasms, urinary pH modifiers, medicines for erectile dysfunction in men and medicines that suppress uterine contractions to prevent preterm labor.

See also

Medical conditions associated with miscellaneous genitourinary tract agents:

  • Abdominal Distension
  • Bladder Infection
  • Cystinuria
  • Dysuria
  • GERD
  • Interstitial Cystitis
  • Metabolic Acidosis
  • Myasthenia Gravis
  • Urinary Retention
  • Urinary Tract Infection

Drug List:


OxyContin


OxyContin is a brand name of oxycodone, approved by the FDA in the following formulation(s):


OXYCONTIN (oxycodone hydrochloride - tablet, extended release; oral)



  • Manufacturer: PURDUE PHARMA LP

    Approval date: April 5, 2010

    Strength(s): 10MG, 15MG, 20MG, 30MG, 40MG [RLD], 60MG, 80MG

Has a generic version of OxyContin been approved?


No. There is currently no therapeutically equivalent version of OxyContin available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OxyContin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Controlled release oxycodone compositions
    Patent 5,508,042
    Issued: April 16, 1996
    Inventor(s): Oshlack; Benjamin & Chasin; Mark & Minogue; John J. & Kaiko; Robert F.
    Assignee(s): Euro-Celtigue, S.A.
    A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e. every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
    Patent expiration dates:

    • April 16, 2013
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME




  • Hot-melt extrudable pharmaceutical formulation
    Patent 6,488,963
    Issued: December 3, 2002
    Inventor(s): James W.; McGinity & Feng; Zhang
    Assignee(s): The University of Texas System
    The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a high molecular weight poly(ethylene oxide) in an essentially non-film like preparation. In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention also includes efficient methods for hot-melt extruding pharmaceutical formulations in essentially non-film preparations.
    Patent expiration dates:

    • June 24, 2017
      ✓ 
      Drug product




  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,674,799
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug product




  • Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
    Patent 7,674,800
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug substance




  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,683,072
    Issued: March 23, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:

    • March 30, 2025
      ✓ 
      Drug substance




  • Abuse-proofed dosage system
    Patent 7,776,314
    Issued: August 17, 2010
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich
    Assignee(s): Grunenthal GmbH
    The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Patent expiration dates:

    • April 19, 2025
      ✓ 
      Drug product




  • Abuse-proofed dosage form
    Patent 8,114,383
    Issued: February 14, 2012
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich & Arkenau-Marić; Elisabeth
    Assignee(s): Gruenenthal GmbH
    The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Patent expiration dates:

    • October 10, 2024
      ✓ 
      Drug product



See also...

  • Oxycontin Consumer Information (Drugs.com)
  • OxyContin Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • OxyContin Consumer Information (Cerner Multum)
  • Oxycontin Advanced Consumer Information (Micromedex)
  • Oxycodone Consumer Information (Drugs.com)
  • Oxycodone Consumer Information (Wolters Kluwer)
  • Oxycodone Concentrate Consumer Information (Wolters Kluwer)
  • Oxycodone Solution Consumer Information (Wolters Kluwer)
  • Oxycodone Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxycodone Consumer Information (Cerner Multum)
  • Oxy IR Advanced Consumer Information (Micromedex)
  • Oxycontin CR Advanced Consumer Information (Micromedex)
  • Oxycodone Advanced Consumer Information (Micromedex)
  • Oxycodone AHFS DI Monographs (ASHP)
  • Oxycodone Hydrochloride AHFS DI Monographs (ASHP)

Renal Vein Thrombosis Medications


There are currently no drugs listed for "Renal Vein Thrombosis".

Definition of Renal Vein Thrombosis: Renal vein thrombosis is a blood clot that develops in the vein that drains the kidney.

Learn more about Renal Vein Thrombosis





Drug List:


Sedaxylan




Sedaxylan may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sedaxylan



Xylazine

Xylazine hydrochloride (a derivative of Xylazine) is reported as an ingredient of Sedaxylan in the following countries:


  • Austria

  • Belgium

  • France

  • Germany

  • Italy

  • Luxembourg

  • Netherlands

  • Portugal

International Drug Name Search


Tuesday, October 25, 2016

Focal Segmental Glomerulosclerosis Medications


Definition of Focal Segmental Glomerulosclerosis:

Focal segmental glomerulosclerosis is scar tissue that forms in parts of the kidney called glomeruli. The glomeruli serve as filters, helping rid the body of unnecessary or harmful substances. Each kidney has thousands of glomeruli. One glomeruli is called a glomerulus. "Focal" means that some of the glomeruli become scarred, while others remain normal. "Segmental" means that only part of an individual glomerulus is damaged.

Drugs associated with Focal Segmental Glomerulosclerosis

The following drugs and medications are in some way related to, or used in the treatment of Focal Segmental Glomerulosclerosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Focal Segmental Glomerulosclerosis





Drug List:


Doryx


Doryx is a brand name of doxycycline, approved by the FDA in the following formulation(s):


DORYX (doxycycline hyclate - tablet, delayed release; oral)



  • Manufacturer: MAYNE PHARMA

    Approval date: May 6, 2005

    Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: MAYNE PHARMA

    Approval date: June 20, 2008

    Strength(s): EQ 150MG BASE [RLD][AB]

Has a generic version of Doryx been approved?


A generic version of Doryx has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Doryx and have been approved by the FDA:


doxycycline hyclate tablet, delayed release; oral



  • Manufacturer: ACTAVIS ELIZABETH

    Approval date: December 14, 2011

    Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: IMPAX LABS INC

    Approval date: December 28, 2010

    Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: December 28, 2010

    Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: MYLAN PHARMS INC

    Approval date: February 8, 2012

    Strength(s): EQ 150MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Doryx. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Modified release coated drug preparation
    Patent 6,958,161
    Issued: October 25, 2005
    Inventor(s): Hayes; David & LoPore; Angelo & Lukas; Stefan & Quinn; Eugene
    Assignee(s): F H Faulding & Co Limited
    A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.
    Patent expiration dates:

    • December 15, 2022
      ✓ 
      Patent use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
      ✓ 
      Drug product



See also...

  • Doryx Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Doryx Delayed-Release Tablets Consumer Information (Wolters Kluwer)
  • Doryx Consumer Information (Cerner Multum)
  • Doryx Advanced Consumer Information (Micromedex)
  • Doxycycline Consumer Information (Drugs.com)
  • Doxycycline Consumer Information (Wolters Kluwer)
  • Doxycycline Capsules Consumer Information (Wolters Kluwer)
  • Doxycycline Hyclate Consumer Information (Wolters Kluwer)
  • Doxycycline Hyclate Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Doxycycline Hyclate Delayed-Release Tablets Consumer Information (Wolters Kluwer)
  • Doxycycline Kit Consumer Information (Wolters Kluwer)
  • Doxycycline Monohydrate Consumer Information (Wolters Kluwer)
  • Doxycycline Suspension Consumer Information (Wolters Kluwer)
  • Doxycycline Syrup Consumer Information (Wolters Kluwer)
  • Doxycycline Tablets Consumer Information (Wolters Kluwer)
  • Doxycycline with Cleanser Consumer Information (Wolters Kluwer)
  • Doxycycline Consumer Information (Cerner Multum)
  • Adoxa Pak Advanced Consumer Information (Micromedex)
  • Atridox Advanced Consumer Information (Micromedex)
  • Vibramycin Hyclate Advanced Consumer Information (Micromedex)
  • Doxycycline Advanced Consumer Information (Micromedex)
  • Doxycycline Subgingival Advanced Consumer Information (Micromedex)
  • Doxycycline AHFS DI Monographs (ASHP)
  • Doxycycline Calcium AHFS DI Monographs (ASHP)
  • Doxycycline Hyclate AHFS DI Monographs (ASHP)
  • Doxycycline Hyclate eent AHFS DI Monographs (ASHP)
  • Doxycycline Monohydrate AHFS DI Monographs (ASHP)

Nitredon




Nitredon may be available in the countries listed below.


Ingredient matches for Nitredon



Nitrazepam

Nitrazepam is reported as an ingredient of Nitredon in the following countries:


  • Cyprus

  • Kenya

  • Malta

  • Sudan

  • Zimbabwe

International Drug Name Search


Valecort




Valecort may be available in the countries listed below.


Ingredient matches for Valecort



Betamethasone

Betamethasone is reported as an ingredient of Valecort in the following countries:


  • Tunisia

International Drug Name Search


Neoral Sandimmun




Neoral Sandimmun may be available in the countries listed below.


Ingredient matches for Neoral Sandimmun



Ciclosporin

Ciclosporin is reported as an ingredient of Neoral Sandimmun in the following countries:


  • Belgium

International Drug Name Search


Dugen




Dugen may be available in the countries listed below.


Ingredient matches for Dugen



Medroxyprogesterone

Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of Dugen in the following countries:


  • Serbia

International Drug Name Search


Sulfamethoxy




Sulfamethoxy may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sulfamethoxy



Sulfamethoxypyridazine

Sulfamethoxypyridazine is reported as an ingredient of Sulfamethoxy in the following countries:


  • Germany

International Drug Name Search


Monday, October 24, 2016

Devapen




Devapen may be available in the countries listed below.


Ingredient matches for Devapen



Benzylpenicillin

Benzylpenicillin is reported as an ingredient of Devapen in the following countries:


  • Georgia

Benzylpenicillin potassium (a derivative of Benzylpenicillin) is reported as an ingredient of Devapen in the following countries:


  • Turkey

Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Devapen in the following countries:


  • Turkey

International Drug Name Search


Hematol




Hematol may be available in the countries listed below.


Ingredient matches for Hematol



Ferrous Sulfate

Ferrous Sulfate is reported as an ingredient of Hematol in the following countries:


  • Bangladesh

International Drug Name Search


Zoloft


Zoloft is a brand name of sertraline, approved by the FDA in the following formulation(s):


ZOLOFT (sertraline hydrochloride - concentrate; oral)



  • Manufacturer: PFIZER

    Approval date: December 7, 1999

    Strength(s): EQ 20MG BASE/ML [RLD][AA]

ZOLOFT (sertraline hydrochloride - tablet; oral)



  • Manufacturer: PFIZER

    Approval date: December 30, 1991

    Strength(s): EQ 100MG BASE [RLD][AB], EQ 50MG BASE [AB]


  • Manufacturer: PFIZER

    Approval date: March 6, 1996

    Strength(s): EQ 25MG BASE [AB]

Has a generic version of Zoloft been approved?


A generic version of Zoloft has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zoloft and have been approved by the FDA:


sertraline hydrochloride concentrate; oral



  • Manufacturer: AUROBINDO PHARMA

    Approval date: October 31, 2008

    Strength(s): EQ 20MG BASE/ML [AA]


  • Manufacturer: RANBAXY

    Approval date: February 5, 2007

    Strength(s): EQ 20MG BASE/ML [AA]

sertraline hydrochloride tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: AUSTARPHARMA LLC

    Approval date: March 4, 2009

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: April 30, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: HIKMA PHARMS

    Approval date: August 10, 2009

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: INVAGEN PHARMS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: LUPIN

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MATRIX LABS LTD

    Approval date: January 31, 2008

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: March 20, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: RANBAXY

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: SUN PHARM INDS (IN)

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: TEVA

    Approval date: August 11, 2006

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: TORRENT PHARMS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: WATSON LABS

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: WOCKHARDT

    Approval date: January 8, 2008

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]


  • Manufacturer: ZYDUS PHARMS USA

    Approval date: February 6, 2007

    Strength(s): EQ 100MG BASE [AB], EQ 25MG BASE [AB], EQ 50MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zoloft. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Sertraline polymorph
    Patent 5,248,699
    Issued: September 28, 1993
    Inventor(s): Sysko; Robert J. & Allen; Douglas J. M.
    Assignee(s): Pfizer Inc.
    This invention relates to a novel crystalline polymorphic form of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4 -tetrahydro-N-methyl-1-naphthalenamine hydrochloride, and to a method for preparing it.
    Patent expiration dates:

    • August 13, 2012


    • February 13, 2013
      ✓ 
      Pediatric exclusivity




  • Sertraline oral concentrate
    Patent 6,727,283
    Issued: April 27, 2004
    Inventor(s): Nancy J.; Harper & Gautam R.; Ranade & Willard M.; Welch
    Assignee(s): Pfizer Inc.
    The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Patent expiration dates:

    • October 11, 2019
      ✓ 
      Patent use: TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
      ✓ 
      Drug product


    • April 11, 2020
      ✓ 
      Pediatric exclusivity




  • Sertraline oral concentrate
    Patent 7,067,555
    Issued: June 27, 2006
    Inventor(s): Harper; Nancy J. & Ranade; Gautam R. & Welch; Willard M.
    Assignee(s): Pfizer Inc
    The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.
    Patent expiration dates:

    • November 10, 2019
      ✓ 
      Drug product


    • May 10, 2020
      ✓ 
      Pediatric exclusivity



See also...

  • Zoloft Consumer Information (Drugs.com)
  • Zoloft Consumer Information (Wolters Kluwer)
  • Zoloft Concentrate Consumer Information (Wolters Kluwer)
  • Zoloft Consumer Information (Cerner Multum)
  • Zoloft Advanced Consumer Information (Micromedex)
  • Zoloft AHFS DI Monographs (ASHP)
  • Sertraline Consumer Information (Drugs.com)
  • Sertraline Consumer Information (Wolters Kluwer)
  • Sertraline Concentrate Consumer Information (Wolters Kluwer)
  • Sertraline Consumer Information (Cerner Multum)
  • Sertraline Advanced Consumer Information (Micromedex)
  • Sertraline Hydrochloride AHFS DI Monographs (ASHP)

Oxaliplatino Milo




Oxaliplatino Milo may be available in the countries listed below.


Ingredient matches for Oxaliplatino Milo



Oxaliplatin

Oxaliplatin is reported as an ingredient of Oxaliplatino Milo in the following countries:


  • Spain

International Drug Name Search


Nansen




Nansen may be available in the countries listed below.


Ingredient matches for Nansen



Omeprazole

Omeprazole is reported as an ingredient of Nansen in the following countries:


  • Italy

International Drug Name Search


Zeroworm




Zeroworm may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Zeroworm



Praziquantel

Praziquantel is reported as an ingredient of Zeroworm in the following countries:


  • South Africa

Pyrantel

Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Zeroworm in the following countries:


  • South Africa

International Drug Name Search


Nutrivisc




Nutrivisc may be available in the countries listed below.


Ingredient matches for Nutrivisc



Povidone

Povidone is reported as an ingredient of Nutrivisc in the following countries:


  • France

International Drug Name Search


Sunday, October 23, 2016

Zalasta




Zalasta may be available in the countries listed below.


Ingredient matches for Zalasta



Olanzapine

Olanzapine is reported as an ingredient of Zalasta in the following countries:


  • Croatia (Hrvatska)

  • Luxembourg

  • Poland

  • Serbia

  • Slovakia

International Drug Name Search


Narocin




Narocin may be available in the countries listed below.


Ingredient matches for Narocin



Naproxen

Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Narocin in the following countries:


  • Israel

International Drug Name Search


Doc Pravastatine




Doc Pravastatine may be available in the countries listed below.


Ingredient matches for Doc Pravastatine



Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Doc Pravastatine in the following countries:


  • Belgium

  • Luxembourg

International Drug Name Search


Vancocina




Vancocina may be available in the countries listed below.


Ingredient matches for Vancocina



Vancomycin

Vancomycin is reported as an ingredient of Vancocina in the following countries:


  • Peru

International Drug Name Search


Traveler's Diarrhea Medications


Definition of Traveler's Diarrhea: An inflammation of the small intestine caused by Escherichia coli bacteria.

Drugs associated with Traveler's Diarrhea

The following drugs and medications are in some way related to, or used in the treatment of Traveler's Diarrhea. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Traveler's Diarrhea

  • Traveler's Diarrhea Prophylaxis (0 drugs)

Learn more about Traveler's Diarrhea





Drug List:


Netilmicin Sulfate




Netilmicin Sulfate may be available in the countries listed below.


Ingredient matches for Netilmicin Sulfate



Netilmicin

Netilmicin Sulfate (JAN, USAN) is known as Netilmicin in the US.

International Drug Name Search

Glossary

JANJapanese Accepted Name
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Oroxine




In the US, Oroxine is a member of the drug class thyroid drugs and is used to treat Hashimoto's disease, Hypothyroidism - After Thyroid Removal, Myxedema Coma, Thyroid Suppression Test, TSH Suppression and Underactive Thyroid.

Ingredient matches for Oroxine



Levothyroxine

Levothyroxine sodium salt (a derivative of Levothyroxine) is reported as an ingredient of Oroxine in the following countries:


  • Australia

  • Bangladesh

  • Malaysia

  • Singapore

International Drug Name Search


Saturday, October 22, 2016

Hestar




Hestar may be available in the countries listed below.


Ingredient matches for Hestar



Hetastarch

Hetastarch is reported as an ingredient of Hestar in the following countries:


  • Oman

Pentalamide

Pentalamide is reported as an ingredient of Hestar in the following countries:


  • Mexico

International Drug Name Search


Varacillin




Varacillin may be available in the countries listed below.


Ingredient matches for Varacillin



Lenampicillin

Lenampicillin hydrochloride (a derivative of Lenampicillin) is reported as an ingredient of Varacillin in the following countries:


  • Japan

International Drug Name Search


Opeclacine




Opeclacine may be available in the countries listed below.


Ingredient matches for Opeclacine



Clarithromycin

Clarithromycin is reported as an ingredient of Opeclacine in the following countries:


  • Vietnam

International Drug Name Search


Nifedipine LA




Nifedipine LA may be available in the countries listed below.


Ingredient matches for Nifedipine LA



Nifedipine

Nifedipine is reported as an ingredient of Nifedipine LA in the following countries:


  • Singapore

International Drug Name Search


Sciomir




Sciomir may be available in the countries listed below.


Ingredient matches for Sciomir



Thiocolchicoside

Thiocolchicoside is reported as an ingredient of Sciomir in the following countries:


  • Italy

International Drug Name Search


Velkacet




Velkacet may be available in the countries listed below.


Ingredient matches for Velkacet



Butamirate

Butamirate citrate (a derivative of Butamirate) is reported as an ingredient of Velkacet in the following countries:


  • Greece

International Drug Name Search


Friday, October 21, 2016

Naproxen sodium and Pseudoephedrine hydrochloride




Ingredient matches for Naproxen sodium and Pseudoephedrine hydrochloride



Naproxen

Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Naproxen sodium and Pseudoephedrine hydrochloride in the following countries:


  • United States

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Naproxen sodium and Pseudoephedrine hydrochloride in the following countries:


  • United States

International Drug Name Search